Fatal COVID-19 pulmonary disease involves ferroptosis

Baiyu Qiu,Fereshteh Zandkarimi,Anjali Saqi,Candace Castagna,Hui Tan,Miroslav Sekulic,Lisa Miorin,Hanina Hibshoosh,Shinya Toyokuni,Koji Uchida,Brent R. Stockwell
DOI: https://doi.org/10.1038/s41467-024-48055-0
IF: 16.6
2024-05-21
Nature Communications
Abstract:SARS-CoV-2 infection causes severe pulmonary manifestations, with poorly understood mechanisms and limited treatment options. Hyperferritinemia and disrupted lung iron homeostasis in COVID-19 patients imply that ferroptosis, an iron-dependent cell death, may occur. Immunostaining and lipidomic analysis in COVID-19 lung autopsies reveal increases in ferroptosis markers, including transferrin receptor 1 and malondialdehyde accumulation in fatal cases. COVID-19 lungs display dysregulation of lipids involved in metabolism and ferroptosis. We find increased ferritin light chain associated with severe COVID-19 lung pathology. Iron overload promotes ferroptosis in both primary cells and cancerous lung epithelial cells. In addition, ferroptosis markers strongly correlate with lung injury severity in a COVID-19 lung disease model using male Syrian hamsters. These results reveal a role for ferroptosis in COVID-19 pulmonary disease; pharmacological ferroptosis inhibition may serve as an adjuvant therapy to prevent lung damage during SARS-CoV-2 infection.
multidisciplinary sciences
What problem does this paper attempt to address?